Sood AK - Search Results

1

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Han HD, et al. Among authors: sood ak. Clin Cancer Res. 2010 Aug 1;16(15):3910-22. doi: 10.1158/1078-0432.CCR-10-0005. Epub 2010 Jun 10. Clin Cancer Res. 2010. PMID: 20538762 Free PMC article.

2

The paradoxical expression of maspin in ovarian carcinoma.

Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ. Sood AK, et al. Clin Cancer Res. 2002 Sep;8(9):2924-32. Clin Cancer Res. 2002. PMID: 12231537

3

Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.

Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK. Cooper BC, et al. Among authors: sood ak. Clin Cancer Res. 2002 Oct;8(10):3193-7. Clin Cancer Res. 2002. PMID: 12374688

4

EphA2 expression is associated with aggressive features in ovarian carcinoma.

Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. Thaker PH, et al. Among authors: sood ak. Clin Cancer Res. 2004 Aug 1;10(15):5145-50. doi: 10.1158/1078-0432.CCR-03-0589. Clin Cancer Res. 2004. PMID: 15297418

5

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sood AK, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5. doi: 10.1158/1078-0432.CCR-04-0574. Clin Cancer Res. 2004. PMID: 15447993 Clinical Trial.

6

Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.

Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK. Thaker PH, et al. Among authors: sood ak. Clin Cancer Res. 2005 Jul 1;11(13):4923-33. doi: 10.1158/1078-0432.CCR-04-2060. Clin Cancer Res. 2005. PMID: 16000591

7

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Landen CN Jr, et al. Among authors: sood ak. Cancer Res. 2005 Aug 1;65(15):6910-8. doi: 10.1158/0008-5472.CAN-05-0530. Cancer Res. 2005. PMID: 16061675

8

Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.

Halder J, Landen CN Jr, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK. Halder J, et al. Among authors: sood ak. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36. doi: 10.1158/1078-0432.CCR-05-1728. Clin Cancer Res. 2005. PMID: 16361572 Free PMC article.

9

Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.

Han LY, Landen CN Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. Han LY, et al. Among authors: sood ak. J Clin Oncol. 2006 Feb 10;24(5):755-61. doi: 10.1200/JCO.2005.02.9181. Epub 2005 Dec 27. J Clin Oncol. 2006. PMID: 16380413

10

Stress hormone-mediated invasion of ovarian cancer cells.

Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW. Sood AK, et al. Clin Cancer Res. 2006 Jan 15;12(2):369-75. doi: 10.1158/1078-0432.CCR-05-1698. Clin Cancer Res. 2006. PMID: 16428474 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,140 results

Search Page